cilofexor
Small moleculeexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02654002)
Timeline
Indications
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1- Mol. weight
- 586.86 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297613 ↗
Also known as
- gs-9674
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04971785 | Phase 2 | Aug 9, 2021 | Gilead Sciences, Novo Nordisk |
| NCT04702490 | Phase 2 | Dec 15, 2020 | Metacrine, Inc. |
| NCT04060147 | Phase 1 | Aug 31, 2019 | Gilead Sciences |
| NCT03987074 | Phase 2 | Aug 31, 2019 | Gilead Sciences, Novo Nordisk |
| NCT03890120 | Phase 3 | Mar 27, 2019 | Gilead Sciences |
| NCT03449446 | Phase 2 | Mar 21, 2018 | Gilead Sciences |
| NCT02943447 | Phase 2 | Dec 1, 2016 | Gilead Sciences |
| NCT02943460 | Phase 2 | Nov 29, 2016 | Gilead Sciences |
| NCT02854605 | Phase 2 | Oct 26, 2016 | Gilead Sciences |
| NCT02808312 | Phase 1 | Jul 13, 2016 | Gilead Sciences |
| NCT02781584 | Phase 2 | Jul 13, 2016 | Gilead Sciences |
| NCT02654002 | Phase 1 | Jan 1, 2016 | Gilead Sciences |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 11 | 11 | 3 | 2016 |
| Novo Nordisk | For profit | 2 | 0 | 1 | 2019 |
| Metacrine, Inc. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1